View Financial HealthReproCELL 배당 및 자사주 매입배당 기준 점검 0/6ReproCELL 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률0%자사주 매입 수익률총 주주 수익률0%미래 배당 수익률0%배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • 1hReproCELL Incorporated announced that it expects to receive ¥376.26356 million in funding from CVI Investments, Inc.Reprocell has announced to 2,932,000 shares at an issue price of ¥ 127 per share for gross proceeds of ¥ 37,23,64,000 and 29,320 17th Series of Stock Acquisition Rights at an issue price of ¥ 133 per unit for gross proceeds of ¥ 3,899,560 for total aggregates of ¥ 376,263,560 on May 27, 2026. The transaction includes new investor participation from CVI Investments. The exercise period starts from June 12 to June 11, 2030 with initial price of ¥ 170 per share. The transaction is expected to close on June 11, 2026.Board Change • May 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. 1 independent director (2 non-independent directors). Independent Outside Director Yoshiyuki Yamakawa was the last independent director to join the board, commencing their role in 2008. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.공시 • May 14ReproCELL Incorporated, Annual General Meeting, Jun 26, 2026ReproCELL Incorporated, Annual General Meeting, Jun 26, 2026.공시 • Mar 05Reprocell Launches Gmp Master Cell Bank Manufacturing For Clinical IpscsREPROCELL announced the launch of its US FDA compliant Good Manufacturing Practice (GMP) Master Cell Bank (MCB) manufacturing service for human induced pluripotent stem cells (iPSCs). Operating from its Beltsville, Maryland facility, REPROCELL offers a comprehensive, end-to-end workflow for clinical iPSC manufacturing. This integrated service spans from StemRNA clinical seed iPSC manufacturing and StemEdit gene editing to GMP Master Cell Bank (MCB) production in compliance with FDA standards. By unifying these critical steps, REPROCELL enables cell therapy developers to accelerate IND submissions while reducing regulatory and manufacturing uncertainty. As part of this platform, the StemRNA Clinical iPSC Seed Clone – LLF-34-F3, derived from US sourced donor material, is supported by an active FDA Drug Master File (DMF). This clone has been expanded into a GMP MCB using FDA-compliant closed system processes. This off-the-shelf GMP iPSC MCB is available for commercial use, providing ready-to-use clinically validated starting material. For sponsors requiring European alignment, REPROCELL offers MCB/WCB manufacturing through its partner, Histocell. This service operates with a GMP certificate and authorization from the Spanish Agency for Medicines and Medical Devices (AEMPS) under European Medicines Agency (EMA) oversight. Donor sourcing and eligibility meet FDA, EMA, and PMDA requirements with full consent for therapeutic use. Footprint-free proprietary RNA reprogramming to generate StemRNA Clinical iPSC Seed Clones under FDA/EMA/PMDA requirements. US-generated StemRNA Clinical Seed Clones supported by an active FDA DMF. Genetic integrity and oncogenic risk assessment using whole-genome sequencing (WGS) for StemRNA Clinical Seed Clones. StemEdit clinical gene editing service, engineered for high on target efficiency with reduced off target activity and lower predicted immunogenicity. GMP MCB manufacturing in compliance with FDA or under EMA and PMDA authorization to manufacture. StemRNA Clinical iPSC Seed Clone – LLF-34-F3 is derived from a healthy O+ female US donor, fully consented for commercial and therapeutic use, and is homozygous at HLA-A and HLA-DPA1 loci enhancing its potential for allogeneic applications. The seed clone meets FDA, EMA and PMDA standards and is supported by a DMF while GMP MCB expansion uses FDA-compliant processes providing a traceable clinically ready starting material. REPROCELL also offers options of StemRNA Clinical iPSC Seed Clones from different donor profiles. This work was supported by a Commercialization Grant (no. 2024-MSCRFCO-6418) from the Maryland Stem Cell Research Fund (MSCRF).공시 • Dec 09ReproCELL Incorporated to Report Q3, 2026 Results on Feb 12, 2026ReproCELL Incorporated announced that they will report Q3, 2026 results on Feb 12, 2026공시 • Sep 02ReproCELL Incorporated to Report Q2, 2026 Results on Nov 13, 2025ReproCELL Incorporated announced that they will report Q2, 2026 results on Nov 13, 2025공시 • Jun 27ReproCELL Incorporated to Report Q1, 2026 Results on Aug 13, 2025ReproCELL Incorporated announced that they will report Q1, 2026 results on Aug 13, 2025공시 • May 14ReproCELL Incorporated, Annual General Meeting, Jun 24, 2025ReproCELL Incorporated, Annual General Meeting, Jun 24, 2025.공시 • Mar 05ReproCELL Incorporated to Report Fiscal Year 2025 Results on May 14, 2025ReproCELL Incorporated announced that they will report fiscal year 2025 results on May 14, 2025공시 • Dec 10ReproCELL Incorporated to Report Q3, 2025 Results on Feb 13, 2025ReproCELL Incorporated announced that they will report Q3, 2025 results on Feb 13, 2025공시 • Aug 27ReproCELL Incorporated to Report Q2, 2025 Results on Nov 13, 2024ReproCELL Incorporated announced that they will report Q2, 2025 results on Nov 13, 2024Reported Earnings • Aug 19First quarter 2025 earnings released: JP¥0.84 loss per share (vs JP¥0.85 profit in 1Q 2024)First quarter 2025 results: JP¥0.84 loss per share (down from JP¥0.85 profit in 1Q 2024). Revenue: JP¥619.0m (up 11% from 1Q 2024). Net loss: JP¥75.0m (down 204% from profit in 1Q 2024). Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.공시 • Jun 06ReproCELL Incorporated to Report Q1, 2025 Results on Aug 13, 2024ReproCELL Incorporated announced that they will report Q1, 2025 results on Aug 13, 2024Reported Earnings • May 16Full year 2024 earnings released: JP¥0.36 loss per share (vs JP¥3.62 loss in FY 2023)Full year 2024 results: JP¥0.36 loss per share (improved from JP¥3.62 loss in FY 2023). Revenue: JP¥2.43b (down 18% from FY 2023). Net loss: JP¥31.0m (loss narrowed 90% from FY 2023). Revenue is forecast to grow 16% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings.공시 • May 15ReproCELL Incorporated, Annual General Meeting, Jun 24, 2024ReproCELL Incorporated, Annual General Meeting, Jun 24, 2024.New Risk • Mar 31New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (JP¥57m net loss in 2 years). Shareholders have been diluted in the past year (3.6% increase in shares outstanding). Market cap is less than US$100m (€85.8m market cap, or US$92.6m).New Risk • Mar 08New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: JP¥218m Forecast net loss in 2 years: JP¥57m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (JP¥57m net loss in 2 years). Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Market cap is less than US$100m (€89.4m market cap, or US$97.8m).공시 • Mar 02ReproCELL Incorporated to Report Fiscal Year 2024 Results on May 13, 2024ReproCELL Incorporated announced that they will report fiscal year 2024 results on May 13, 2024New Risk • Feb 21New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Market cap is less than US$100m (€89.2m market cap, or US$96.5m).Reported Earnings • Feb 11Third quarter 2024 earnings released: JP¥0.14 loss per share (vs JP¥1.26 loss in 3Q 2023)Third quarter 2024 results: JP¥0.14 loss per share (improved from JP¥1.26 loss in 3Q 2023). Revenue: JP¥629.0m (down 2.8% from 3Q 2023). Net loss: JP¥12.0m (loss narrowed 89% from 3Q 2023). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.Breakeven Date Change • Dec 23Forecast breakeven date pushed back to 2026The analyst covering ReproCELL previously expected the company to break even in 2025. New forecast suggests losses will reduce by 56% per year to 2025. The company is expected to make a profit of JP¥100.0m in 2026. Average annual earnings growth of 96% is required to achieve expected profit on schedule.공시 • Dec 03ReproCELL Incorporated to Report Q3, 2024 Results on Feb 09, 2024ReproCELL Incorporated announced that they will report Q3, 2024 results on Feb 09, 2024Reported Earnings • Nov 12Second quarter 2024 earnings released: JP¥0.14 loss per share (vs JP¥0.31 profit in 2Q 2023)Second quarter 2024 results: JP¥0.14 loss per share (down from JP¥0.31 profit in 2Q 2023). Revenue: JP¥591.0m (down 35% from 2Q 2023). Net loss: JP¥12.0m (down 146% from profit in 2Q 2023). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.New Risk • Nov 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.공시 • Aug 25ReproCELL Incorporated to Report Q2, 2024 Results on Nov 10, 2023ReproCELL Incorporated announced that they will report Q2, 2024 results on Nov 10, 2023Reported Earnings • Aug 13First quarter 2024 earnings released: EPS: JP¥0.85 (vs JP¥0.51 in 1Q 2023)First quarter 2024 results: EPS: JP¥0.85 (up from JP¥0.51 in 1Q 2023). Revenue: JP¥556.0m (down 17% from 1Q 2023). Net income: JP¥72.0m (up 71% from 1Q 2023). Profit margin: 13% (up from 6.3% in 1Q 2023). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.공시 • May 28ReproCELL Incorporated to Report Q1, 2024 Results on Aug 10, 2023ReproCELL Incorporated announced that they will report Q1, 2024 results on Aug 10, 2023Breakeven Date Change • May 22Forecast to breakeven in 2025The analyst covering ReproCELL expects the company to break even for the first time. New forecast suggests losses will reduce by 48% to 2024. The company is expected to make a profit of JP¥30.0m in 2025. Average annual earnings growth of 98% is required to achieve expected profit on schedule.Reported Earnings • May 17Full year 2023 earnings released: JP¥3.62 loss per share (vs JP¥7.57 loss in FY 2022)Full year 2023 results: JP¥3.62 loss per share (improved from JP¥7.57 loss in FY 2022). Revenue: JP¥2.95b (up 32% from FY 2022). Net loss: JP¥305.0m (loss narrowed 47% from FY 2022). Revenue is forecast to stay flat during the next 2 years compared to a 19% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.공시 • May 14ReproCELL Incorporated, Annual General Meeting, Jun 22, 2023ReproCELL Incorporated, Annual General Meeting, Jun 22, 2023.Reported Earnings • Feb 12Third quarter 2023 earnings released: JP¥1.26 loss per share (vs JP¥1.94 loss in 3Q 2022)Third quarter 2023 results: JP¥1.26 loss per share (improved from JP¥1.94 loss in 3Q 2022). Revenue: JP¥647.0m (up 30% from 3Q 2022). Net loss: JP¥107.0m (loss narrowed 29% from 3Q 2022). Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.공시 • Dec 18ReproCELL Incorporated to Report Q3, 2023 Results on Feb 10, 2023ReproCELL Incorporated announced that they will report Q3, 2023 results on Feb 10, 2023Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. No independent directors (4 non-independent directors). External Auditor Akira Ishikawa was the last director to join the board, commencing their role in 2012. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • Aug 12First quarter 2023 earnings released: EPS: JP¥0.51 (vs JP¥1.70 loss in 1Q 2022)First quarter 2023 results: EPS: JP¥0.51 (up from JP¥1.70 loss in 1Q 2022). Revenue: JP¥666.0m (up 74% from 1Q 2022). Net income: JP¥42.0m (up JP¥164.0m from 1Q 2022). Profit margin: 6.3% (up from net loss in 1Q 2022). The move to profitability was driven by higher revenue. Over the next year, revenue is expected to shrink by 4.4% compared to a 10% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.공시 • Jul 01ReproCELL Incorporated to Report Q1, 2023 Results on Aug 10, 2022ReproCELL Incorporated announced that they will report Q1, 2023 results on Aug 10, 2022공시 • May 18ReproCELL Incorporated, Annual General Meeting, Jun 24, 2022ReproCELL Incorporated, Annual General Meeting, Jun 24, 2022.Reported Earnings • May 16Full year 2022 earnings released: JP¥7.57 loss per share (vs JP¥11.37 loss in FY 2021)Full year 2022 results: JP¥7.57 loss per share (up from JP¥11.37 loss in FY 2021). Revenue: JP¥2.23b (up 74% from FY 2021). Net loss: JP¥575.0m (loss narrowed 29% from FY 2021). Over the next year, revenue is expected to shrink by 12% compared to a 36% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. No independent directors (4 non-independent directors). External Auditor Akira Ishikawa was the last director to join the board, commencing their role in 2012. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.공시 • Apr 08ReproCELL Incorporated to Report Fiscal Year 2022 Results on May 13, 2022ReproCELL Incorporated announced that they will report fiscal year 2022 results on May 13, 2022Reported Earnings • Feb 11Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beatThird quarter 2022 results: JP¥1.94 loss per share (up from JP¥4.10 loss in 3Q 2021). Revenue: JP¥499.0m (up 49% from 3Q 2021). Net loss: JP¥150.0m (loss narrowed 49% from 3Q 2021). Revenue exceeded analyst estimates by 11%. Over the next year, revenue is forecast to grow 31%, compared to a 61% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.Reported Earnings • Nov 15Second quarter 2022 earnings released: JP¥1.08 loss per share (vs JP¥2.20 loss in 2Q 2021)The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2022 results: Revenue: JP¥607.0m (up 36% from 2Q 2021). Net loss: JP¥79.0m (loss narrowed 50% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.공시 • Jun 18ReproCELL Incorporated announced that it has received ¥17.69 million in funding from SMBC Nikko Securities Inc., Investment ArmOn June 17, 2021, ReproCELL Incorporated (JASDAQ:4978) closed the transaction.Breakeven Date Change • Jun 04Forecast to breakeven in 2024The analyst covering ReproCELL expects the company to break even for the first time. New forecast suggests losses will reduce by 38% per year to 2023. The company is expected to make a profit of JP¥150.0m in 2024. Average annual earnings growth of 70% is required to achieve expected profit on schedule.공시 • Jun 02ReproCELL Incorporated announced that it expects to receive ¥17.69 million in funding from SMBC Nikko Securities Inc., Investment ArmReproCELL, Inc. (JASDAQ:4978) announced a private placement of 145,000 15th series warrants at a price of ¥122 per warrant with SMBC Nikko Securities Inc., Investment Arm for gross proceeds of ¥17,690,000 on June 1, 2021. The warrants are exercisable into 14,500,000 common shares of the company at an exercise price of ¥371 per share from June 18, 2021 to June 28, 2024. The warrants will be issued by third party allocation. The net proceeds from the transaction will be ¥15,862,000. The company will bear expenses for various expenses for the issuance including attorney fees, value calculation expense, and trust bank expense. The transaction has been approved by the board of directors of the company. The allotment date is December June 17, 2021.Reported Earnings • May 14Full year 2021 earnings released: JP¥11.37 loss per share (vs JP¥14.26 loss in FY 2020)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: JP¥1.29b (up 7.3% from FY 2020). Net loss: JP¥812.0m (loss narrowed 20% from FY 2020). Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.공시 • Mar 04ReproCELL Incorporated to Report Fiscal Year 2021 Results on May 14, 2021ReproCELL Incorporated announced that they will report fiscal year 2021 results on May 14, 2021Is New 90 Day High Low • Feb 27New 90-day low: €2.94The company is down 5.0% from its price of €3.08 on 27 November 2020. The German market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 2.0% over the same period.Analyst Estimate Surprise Post Earnings • Feb 14Revenue beats expectationsRevenue exceeded analyst estimates by 1.5%. Over the next year, revenue is forecast to grow 37%, compared to a 76% growth forecast for the Biotechs industry in Germany.Reported Earnings • Feb 14Third quarter 2021 earnings released: JP¥4.10 loss per share (vs JP¥3.18 loss in 3Q 2020)The company reported a soft third quarter result with increased losses and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: JP¥335.0m (up 2.4% from 3Q 2020). Net loss: JP¥293.0m (loss widened 29% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth.Is New 90 Day High Low • Jan 26New 90-day high: €3.48The company is up 16% from its price of €3.00 on 28 October 2020. The German market is also up 16% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Biotechs industry, which is up 12% over the same period.공시 • Nov 29ReproCELL Incorporated to Report Q3, 2021 Results on Feb 12, 2021ReproCELL Incorporated announced that they will report Q3, 2021 results on Feb 12, 2021Reported Earnings • Nov 13Second quarter 2021 earnings released: JP¥2.20 loss per shareThe company reported a solid second quarter result with reduced losses and improved revenues and control over expenses. Second quarter 2021 results: Revenue: JP¥446.0m (up 45% from 2Q 2020). Net loss: JP¥157.0m (loss narrowed 24% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.Is New 90 Day High Low • Nov 11New 90-day low: €2.88The company is down 15% from its price of €3.38 on 13 August 2020. The German market is flat over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 18% over the same period.공시 • Oct 10ReproCELL Incorporated to Report Q2, 2021 Results on Nov 12, 2020ReproCELL Incorporated announced that they will report Q2, 2021 results on Nov 12, 2020Reported Earnings • Oct 01First quarter earnings releasedOver the last 12 months the company has reported total losses of JP¥995.0m, with losses widening by 33% from the prior year. Total revenue was JP¥1.11b over the last 12 months, up 1.9% from the prior year.Is New 90 Day High Low • Sep 29New 90-day low: €2.92The company is down 18% from its price of €3.54 on 01 July 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 2.0% over the same period.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 6RC 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: 6RC 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장ReproCELL 배당 수익률 vs 시장6RC의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (6RC)n/a시장 하위 25% (DE)1.5%시장 상위 25% (DE)4.6%업계 평균 (Biotechs)2.1%분석가 예측 (6RC) (최대 3년)0%주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 6RC 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 6RC 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 6RC 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: 6RC 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YDE 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/27 19:10종가2026/05/27 00:00수익2026/03/31연간 수익2026/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스ReproCELL Incorporated는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Akinori UedaGoldman Sachs
공시 • 1hReproCELL Incorporated announced that it expects to receive ¥376.26356 million in funding from CVI Investments, Inc.Reprocell has announced to 2,932,000 shares at an issue price of ¥ 127 per share for gross proceeds of ¥ 37,23,64,000 and 29,320 17th Series of Stock Acquisition Rights at an issue price of ¥ 133 per unit for gross proceeds of ¥ 3,899,560 for total aggregates of ¥ 376,263,560 on May 27, 2026. The transaction includes new investor participation from CVI Investments. The exercise period starts from June 12 to June 11, 2030 with initial price of ¥ 170 per share. The transaction is expected to close on June 11, 2026.
Board Change • May 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. 1 independent director (2 non-independent directors). Independent Outside Director Yoshiyuki Yamakawa was the last independent director to join the board, commencing their role in 2008. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
공시 • May 14ReproCELL Incorporated, Annual General Meeting, Jun 26, 2026ReproCELL Incorporated, Annual General Meeting, Jun 26, 2026.
공시 • Mar 05Reprocell Launches Gmp Master Cell Bank Manufacturing For Clinical IpscsREPROCELL announced the launch of its US FDA compliant Good Manufacturing Practice (GMP) Master Cell Bank (MCB) manufacturing service for human induced pluripotent stem cells (iPSCs). Operating from its Beltsville, Maryland facility, REPROCELL offers a comprehensive, end-to-end workflow for clinical iPSC manufacturing. This integrated service spans from StemRNA clinical seed iPSC manufacturing and StemEdit gene editing to GMP Master Cell Bank (MCB) production in compliance with FDA standards. By unifying these critical steps, REPROCELL enables cell therapy developers to accelerate IND submissions while reducing regulatory and manufacturing uncertainty. As part of this platform, the StemRNA Clinical iPSC Seed Clone – LLF-34-F3, derived from US sourced donor material, is supported by an active FDA Drug Master File (DMF). This clone has been expanded into a GMP MCB using FDA-compliant closed system processes. This off-the-shelf GMP iPSC MCB is available for commercial use, providing ready-to-use clinically validated starting material. For sponsors requiring European alignment, REPROCELL offers MCB/WCB manufacturing through its partner, Histocell. This service operates with a GMP certificate and authorization from the Spanish Agency for Medicines and Medical Devices (AEMPS) under European Medicines Agency (EMA) oversight. Donor sourcing and eligibility meet FDA, EMA, and PMDA requirements with full consent for therapeutic use. Footprint-free proprietary RNA reprogramming to generate StemRNA Clinical iPSC Seed Clones under FDA/EMA/PMDA requirements. US-generated StemRNA Clinical Seed Clones supported by an active FDA DMF. Genetic integrity and oncogenic risk assessment using whole-genome sequencing (WGS) for StemRNA Clinical Seed Clones. StemEdit clinical gene editing service, engineered for high on target efficiency with reduced off target activity and lower predicted immunogenicity. GMP MCB manufacturing in compliance with FDA or under EMA and PMDA authorization to manufacture. StemRNA Clinical iPSC Seed Clone – LLF-34-F3 is derived from a healthy O+ female US donor, fully consented for commercial and therapeutic use, and is homozygous at HLA-A and HLA-DPA1 loci enhancing its potential for allogeneic applications. The seed clone meets FDA, EMA and PMDA standards and is supported by a DMF while GMP MCB expansion uses FDA-compliant processes providing a traceable clinically ready starting material. REPROCELL also offers options of StemRNA Clinical iPSC Seed Clones from different donor profiles. This work was supported by a Commercialization Grant (no. 2024-MSCRFCO-6418) from the Maryland Stem Cell Research Fund (MSCRF).
공시 • Dec 09ReproCELL Incorporated to Report Q3, 2026 Results on Feb 12, 2026ReproCELL Incorporated announced that they will report Q3, 2026 results on Feb 12, 2026
공시 • Sep 02ReproCELL Incorporated to Report Q2, 2026 Results on Nov 13, 2025ReproCELL Incorporated announced that they will report Q2, 2026 results on Nov 13, 2025
공시 • Jun 27ReproCELL Incorporated to Report Q1, 2026 Results on Aug 13, 2025ReproCELL Incorporated announced that they will report Q1, 2026 results on Aug 13, 2025
공시 • May 14ReproCELL Incorporated, Annual General Meeting, Jun 24, 2025ReproCELL Incorporated, Annual General Meeting, Jun 24, 2025.
공시 • Mar 05ReproCELL Incorporated to Report Fiscal Year 2025 Results on May 14, 2025ReproCELL Incorporated announced that they will report fiscal year 2025 results on May 14, 2025
공시 • Dec 10ReproCELL Incorporated to Report Q3, 2025 Results on Feb 13, 2025ReproCELL Incorporated announced that they will report Q3, 2025 results on Feb 13, 2025
공시 • Aug 27ReproCELL Incorporated to Report Q2, 2025 Results on Nov 13, 2024ReproCELL Incorporated announced that they will report Q2, 2025 results on Nov 13, 2024
Reported Earnings • Aug 19First quarter 2025 earnings released: JP¥0.84 loss per share (vs JP¥0.85 profit in 1Q 2024)First quarter 2025 results: JP¥0.84 loss per share (down from JP¥0.85 profit in 1Q 2024). Revenue: JP¥619.0m (up 11% from 1Q 2024). Net loss: JP¥75.0m (down 204% from profit in 1Q 2024). Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.
공시 • Jun 06ReproCELL Incorporated to Report Q1, 2025 Results on Aug 13, 2024ReproCELL Incorporated announced that they will report Q1, 2025 results on Aug 13, 2024
Reported Earnings • May 16Full year 2024 earnings released: JP¥0.36 loss per share (vs JP¥3.62 loss in FY 2023)Full year 2024 results: JP¥0.36 loss per share (improved from JP¥3.62 loss in FY 2023). Revenue: JP¥2.43b (down 18% from FY 2023). Net loss: JP¥31.0m (loss narrowed 90% from FY 2023). Revenue is forecast to grow 16% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings.
공시 • May 15ReproCELL Incorporated, Annual General Meeting, Jun 24, 2024ReproCELL Incorporated, Annual General Meeting, Jun 24, 2024.
New Risk • Mar 31New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (JP¥57m net loss in 2 years). Shareholders have been diluted in the past year (3.6% increase in shares outstanding). Market cap is less than US$100m (€85.8m market cap, or US$92.6m).
New Risk • Mar 08New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: JP¥218m Forecast net loss in 2 years: JP¥57m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (JP¥57m net loss in 2 years). Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Market cap is less than US$100m (€89.4m market cap, or US$97.8m).
공시 • Mar 02ReproCELL Incorporated to Report Fiscal Year 2024 Results on May 13, 2024ReproCELL Incorporated announced that they will report fiscal year 2024 results on May 13, 2024
New Risk • Feb 21New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Market cap is less than US$100m (€89.2m market cap, or US$96.5m).
Reported Earnings • Feb 11Third quarter 2024 earnings released: JP¥0.14 loss per share (vs JP¥1.26 loss in 3Q 2023)Third quarter 2024 results: JP¥0.14 loss per share (improved from JP¥1.26 loss in 3Q 2023). Revenue: JP¥629.0m (down 2.8% from 3Q 2023). Net loss: JP¥12.0m (loss narrowed 89% from 3Q 2023). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.
Breakeven Date Change • Dec 23Forecast breakeven date pushed back to 2026The analyst covering ReproCELL previously expected the company to break even in 2025. New forecast suggests losses will reduce by 56% per year to 2025. The company is expected to make a profit of JP¥100.0m in 2026. Average annual earnings growth of 96% is required to achieve expected profit on schedule.
공시 • Dec 03ReproCELL Incorporated to Report Q3, 2024 Results on Feb 09, 2024ReproCELL Incorporated announced that they will report Q3, 2024 results on Feb 09, 2024
Reported Earnings • Nov 12Second quarter 2024 earnings released: JP¥0.14 loss per share (vs JP¥0.31 profit in 2Q 2023)Second quarter 2024 results: JP¥0.14 loss per share (down from JP¥0.31 profit in 2Q 2023). Revenue: JP¥591.0m (down 35% from 2Q 2023). Net loss: JP¥12.0m (down 146% from profit in 2Q 2023). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.
New Risk • Nov 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
공시 • Aug 25ReproCELL Incorporated to Report Q2, 2024 Results on Nov 10, 2023ReproCELL Incorporated announced that they will report Q2, 2024 results on Nov 10, 2023
Reported Earnings • Aug 13First quarter 2024 earnings released: EPS: JP¥0.85 (vs JP¥0.51 in 1Q 2023)First quarter 2024 results: EPS: JP¥0.85 (up from JP¥0.51 in 1Q 2023). Revenue: JP¥556.0m (down 17% from 1Q 2023). Net income: JP¥72.0m (up 71% from 1Q 2023). Profit margin: 13% (up from 6.3% in 1Q 2023). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.
공시 • May 28ReproCELL Incorporated to Report Q1, 2024 Results on Aug 10, 2023ReproCELL Incorporated announced that they will report Q1, 2024 results on Aug 10, 2023
Breakeven Date Change • May 22Forecast to breakeven in 2025The analyst covering ReproCELL expects the company to break even for the first time. New forecast suggests losses will reduce by 48% to 2024. The company is expected to make a profit of JP¥30.0m in 2025. Average annual earnings growth of 98% is required to achieve expected profit on schedule.
Reported Earnings • May 17Full year 2023 earnings released: JP¥3.62 loss per share (vs JP¥7.57 loss in FY 2022)Full year 2023 results: JP¥3.62 loss per share (improved from JP¥7.57 loss in FY 2022). Revenue: JP¥2.95b (up 32% from FY 2022). Net loss: JP¥305.0m (loss narrowed 47% from FY 2022). Revenue is forecast to stay flat during the next 2 years compared to a 19% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.
공시 • May 14ReproCELL Incorporated, Annual General Meeting, Jun 22, 2023ReproCELL Incorporated, Annual General Meeting, Jun 22, 2023.
Reported Earnings • Feb 12Third quarter 2023 earnings released: JP¥1.26 loss per share (vs JP¥1.94 loss in 3Q 2022)Third quarter 2023 results: JP¥1.26 loss per share (improved from JP¥1.94 loss in 3Q 2022). Revenue: JP¥647.0m (up 30% from 3Q 2022). Net loss: JP¥107.0m (loss narrowed 29% from 3Q 2022). Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
공시 • Dec 18ReproCELL Incorporated to Report Q3, 2023 Results on Feb 10, 2023ReproCELL Incorporated announced that they will report Q3, 2023 results on Feb 10, 2023
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. No independent directors (4 non-independent directors). External Auditor Akira Ishikawa was the last director to join the board, commencing their role in 2012. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • Aug 12First quarter 2023 earnings released: EPS: JP¥0.51 (vs JP¥1.70 loss in 1Q 2022)First quarter 2023 results: EPS: JP¥0.51 (up from JP¥1.70 loss in 1Q 2022). Revenue: JP¥666.0m (up 74% from 1Q 2022). Net income: JP¥42.0m (up JP¥164.0m from 1Q 2022). Profit margin: 6.3% (up from net loss in 1Q 2022). The move to profitability was driven by higher revenue. Over the next year, revenue is expected to shrink by 4.4% compared to a 10% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
공시 • Jul 01ReproCELL Incorporated to Report Q1, 2023 Results on Aug 10, 2022ReproCELL Incorporated announced that they will report Q1, 2023 results on Aug 10, 2022
공시 • May 18ReproCELL Incorporated, Annual General Meeting, Jun 24, 2022ReproCELL Incorporated, Annual General Meeting, Jun 24, 2022.
Reported Earnings • May 16Full year 2022 earnings released: JP¥7.57 loss per share (vs JP¥11.37 loss in FY 2021)Full year 2022 results: JP¥7.57 loss per share (up from JP¥11.37 loss in FY 2021). Revenue: JP¥2.23b (up 74% from FY 2021). Net loss: JP¥575.0m (loss narrowed 29% from FY 2021). Over the next year, revenue is expected to shrink by 12% compared to a 36% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. No independent directors (4 non-independent directors). External Auditor Akira Ishikawa was the last director to join the board, commencing their role in 2012. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
공시 • Apr 08ReproCELL Incorporated to Report Fiscal Year 2022 Results on May 13, 2022ReproCELL Incorporated announced that they will report fiscal year 2022 results on May 13, 2022
Reported Earnings • Feb 11Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beatThird quarter 2022 results: JP¥1.94 loss per share (up from JP¥4.10 loss in 3Q 2021). Revenue: JP¥499.0m (up 49% from 3Q 2021). Net loss: JP¥150.0m (loss narrowed 49% from 3Q 2021). Revenue exceeded analyst estimates by 11%. Over the next year, revenue is forecast to grow 31%, compared to a 61% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
Reported Earnings • Nov 15Second quarter 2022 earnings released: JP¥1.08 loss per share (vs JP¥2.20 loss in 2Q 2021)The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2022 results: Revenue: JP¥607.0m (up 36% from 2Q 2021). Net loss: JP¥79.0m (loss narrowed 50% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
공시 • Jun 18ReproCELL Incorporated announced that it has received ¥17.69 million in funding from SMBC Nikko Securities Inc., Investment ArmOn June 17, 2021, ReproCELL Incorporated (JASDAQ:4978) closed the transaction.
Breakeven Date Change • Jun 04Forecast to breakeven in 2024The analyst covering ReproCELL expects the company to break even for the first time. New forecast suggests losses will reduce by 38% per year to 2023. The company is expected to make a profit of JP¥150.0m in 2024. Average annual earnings growth of 70% is required to achieve expected profit on schedule.
공시 • Jun 02ReproCELL Incorporated announced that it expects to receive ¥17.69 million in funding from SMBC Nikko Securities Inc., Investment ArmReproCELL, Inc. (JASDAQ:4978) announced a private placement of 145,000 15th series warrants at a price of ¥122 per warrant with SMBC Nikko Securities Inc., Investment Arm for gross proceeds of ¥17,690,000 on June 1, 2021. The warrants are exercisable into 14,500,000 common shares of the company at an exercise price of ¥371 per share from June 18, 2021 to June 28, 2024. The warrants will be issued by third party allocation. The net proceeds from the transaction will be ¥15,862,000. The company will bear expenses for various expenses for the issuance including attorney fees, value calculation expense, and trust bank expense. The transaction has been approved by the board of directors of the company. The allotment date is December June 17, 2021.
Reported Earnings • May 14Full year 2021 earnings released: JP¥11.37 loss per share (vs JP¥14.26 loss in FY 2020)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: JP¥1.29b (up 7.3% from FY 2020). Net loss: JP¥812.0m (loss narrowed 20% from FY 2020). Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.
공시 • Mar 04ReproCELL Incorporated to Report Fiscal Year 2021 Results on May 14, 2021ReproCELL Incorporated announced that they will report fiscal year 2021 results on May 14, 2021
Is New 90 Day High Low • Feb 27New 90-day low: €2.94The company is down 5.0% from its price of €3.08 on 27 November 2020. The German market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 2.0% over the same period.
Analyst Estimate Surprise Post Earnings • Feb 14Revenue beats expectationsRevenue exceeded analyst estimates by 1.5%. Over the next year, revenue is forecast to grow 37%, compared to a 76% growth forecast for the Biotechs industry in Germany.
Reported Earnings • Feb 14Third quarter 2021 earnings released: JP¥4.10 loss per share (vs JP¥3.18 loss in 3Q 2020)The company reported a soft third quarter result with increased losses and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: JP¥335.0m (up 2.4% from 3Q 2020). Net loss: JP¥293.0m (loss widened 29% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth.
Is New 90 Day High Low • Jan 26New 90-day high: €3.48The company is up 16% from its price of €3.00 on 28 October 2020. The German market is also up 16% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Biotechs industry, which is up 12% over the same period.
공시 • Nov 29ReproCELL Incorporated to Report Q3, 2021 Results on Feb 12, 2021ReproCELL Incorporated announced that they will report Q3, 2021 results on Feb 12, 2021
Reported Earnings • Nov 13Second quarter 2021 earnings released: JP¥2.20 loss per shareThe company reported a solid second quarter result with reduced losses and improved revenues and control over expenses. Second quarter 2021 results: Revenue: JP¥446.0m (up 45% from 2Q 2020). Net loss: JP¥157.0m (loss narrowed 24% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
Is New 90 Day High Low • Nov 11New 90-day low: €2.88The company is down 15% from its price of €3.38 on 13 August 2020. The German market is flat over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 18% over the same period.
공시 • Oct 10ReproCELL Incorporated to Report Q2, 2021 Results on Nov 12, 2020ReproCELL Incorporated announced that they will report Q2, 2021 results on Nov 12, 2020
Reported Earnings • Oct 01First quarter earnings releasedOver the last 12 months the company has reported total losses of JP¥995.0m, with losses widening by 33% from the prior year. Total revenue was JP¥1.11b over the last 12 months, up 1.9% from the prior year.
Is New 90 Day High Low • Sep 29New 90-day low: €2.92The company is down 18% from its price of €3.54 on 01 July 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 2.0% over the same period.